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Open access underwarfarin. It is unknown whether the increased risk is unique to dabigatran, an adverse
effect shared by other oral direct thrombin inhibitors (DTIs), or the result of a protective
effect of warfarin against MI. To address these questions, we systematically searched
MEDLINE and performed a meta-analysis on randomized trials that compared oral DTIs
with warfarin for any indication with end point of MIs after randomization. We further-
more performed a secondary meta-analysis on atrial ﬁbrillation stroke prevention trials
with alternative anticoagulants compared with warfarin with end point of MIs after
randomization. A total of 11 trials (39,357 patients) that compared warfarin to DTIs
(dabigatran, ximelagatran, and AZD0837) were identiﬁed. In these trials, patients treated
with oral DTIs were more likely to experience an MI than their counterparts treated with
warfarin (285 of 23,333 vs 133 of 16,024, odds ratio 1.35, 95% conﬁdence interval 1.10 to
1.66, p [ 0.005). For secondary analysis, 8 studies (69,615 patients) were identiﬁed that
compared warfarin with alternative anticoagulant including factor Xa inhibitors, DTIs,
aspirin, and clopidogrel. There was no signiﬁcant advantage in the rate of MIs with the use
of warfarin versus comparators (odds ratio 1.06, 95% conﬁdence interval 0.85 to 1.34, p[
0.59). In conclusion, our data suggest that oral DTIs were associated with increased risk of
MI. This increased risk appears to be a class effect of these agents, not a speciﬁc
phenomenon unique to dabigatran or protective effect of warfarin. These ﬁndings support
the need for enhanced postmarket surveillance of oral DTIs and other novel
agents.Inc. (AmOpen access under CC BY-NC-ND license. 2013 The Authors. Published by Elsevier
J Cardiol 2013;112:1973e1979)
The use of the oral direct thrombin inhibitor (DTI),
dabigatran, was associated with lower rates of stroke and
systemic embolism compared with warfarin demonstrated
in the Randomized Evaluation of Long-term Anti-
coagulation Therapy (RE-LY) trial.1 The study also
revealed that a higher rate of clinical myocardial infarction
(MI) was observed with dabigatran than with warfarin that
was found to be statistically not signiﬁcant in the post hoc
analysis.2 A recent meta-analysis revealed that the rate of
coronary events was increased with the use of dabigatran
compared with various types of controls.3 Ximelagatran,
another oral thrombin inhibitor no longer available for
clinical use, was associated with a signiﬁcantly increasedrdial ischemia compared with warfarin in
ad acute deep vein thrombosis.4 It has been
Nebraska Medical Center, Division of Cardiology,
; bRigshospitalet, Division of Hematology, Copenhagen,
arshﬁeld Clinic, Marshﬁeld Clinic Research Foundation,
nsin. Manuscript received July 22, 2013; revised manu-
accepted August 6, 2013.
for disclosure information.
g author: Tel: (712) 301-8300; fax: (712) 294-7042.
s: ramin_artang@yahoo.com (R. Artang).
013 The Authors. Published by Elsevier Inc.
0.1016/j.amjcard.2013.08.027
 CC BY-NC-ND license.proposed that warfarin might provide a protective effect
against MI compared with non-warfarin anticoagulants in
patients with atrial ﬁbrillation who are prescribed anti-
coagulation for stroke thromboprophylaxis.5 The purpose
of this study was twofold. The ﬁrst objective was to
investigate whether the excess rate of MIs with dabigatran
compared with warfarin was related to the effect of dabi-
gatran alone or was an effect consistent for the entire class of
oral DTIs. The second objective was to evaluate whether the
use of warfarin indeed is associated with less incidence
of MI in the more recent large-scale atrial ﬁbrillation
stroke prevention trials compared with non-warfarin
anticoagulants.
Methods
This meta-analysis followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guide-
lines.6 To reduce the signal-to-noise ratio, a deliberate
decision was made to include only the data on “myocardial
infarction” as compared with “acute coronary syndrome”
or other coronary ischemia related terms that are more
likely to be inﬂuenced by subjective interpretation because
detailed description of clinical history at the time of initial
presentation or information on electrocardiographic
changes, cardiac enzyme levels, and the result of possible
coronary ischemia evaluation was not disclosed in the
individual published trials. Based on the objectives ofwww.ajconline.org
Figure 1. Flow diagram of the study selection for comparison of oral DTIs versus warfarin.
1974 The American Journal of Cardiology (www.ajconline.org)the study, we performed 2 separate systematic literature
searches.
To address the observation of incidence of MI in trials
with oral DTIs, we searched MEDLINE, Embase, and the
Cochrane Collaboration, up to March 2013 using key
words: “oral,” “direct thrombin inhibitor” with the limiting
term “clinical trial” without language or publication date
restrictions. We then performed a secondary search using
the individual agent name: “dabigatran” with the limiting
term “clinical trial,” “ximelagatran” with the limiting term
“clinical trial,” and lastly “AZD0837” and “soﬁgatran”with
no limitations. Studies were included in meta-analysis if (1)
the comparison between an oral DTI and warfarin was made
for any indication and (2) the occurrence of MI after
randomization was reported by investigators by any
deﬁnition.
Regarding the possible protective effect of warfarin in pre-
venting MI in more recent atrial ﬁbrillation stroke prevention
trials, we performed a MEDLINE search using the PubMed
medical subject heading database using terms: “atrial ﬁbrilla-
tion,” “stroke prevention and control,” “anticoagulants/thera-
peutic use,” and “warfarin/therapeutic use” with the limiting
term of “randomized trials” and time limit of “10 years.”
Studies were included in the meta-analysis if (1) comparison
between warfarin and any alternative antithrombotic agent was
performed and (2) the occurrence of MI after randomization
was reported by investigators by any deﬁnition.
The data were analyzed using Comprehensive Meta-
Analysis, version 2 (Biostat, Englewood, New Jersey). The
pooled odds ratio (OR) with 95% conﬁdence interval
(CI) for MI was calculated using the ﬁxed-effects
Mantel-Haenszel model, whereas in the case of signiﬁcant
heterogeneity across studies, the random-effects model wasused instead. The likelihood of statistical heterogeneity was
assessed using the Cochrane Q test and quantiﬁed with the
I2 statistic. An I2 >50% was considered statistically
signiﬁcant heterogeneity. In addition, an inﬂuence analysis,
in which meta-analysis estimates are computed omitting 1
study at a time, was performed for the primary end point.
Publication bias was evaluated with the funnel plot and the
Egger regression test.
Results
The results of the literature search on oral DTIs versus
warfarin are shown in Figure 1. A total of 676 publications
were identiﬁed and screened. Of those, 14 full-text manu-
scripts were found eligible for detail review. Eleven
randomized controlled trials fulﬁlled the inclusion criteria
and were selected for meta-analysis, with the total number
of 39,357 participants. The individual study details are lis-
ted in Table 1. TheMI deﬁnition was prespeciﬁed in the trial
design in less than half of the studies. None of the studies
had prespeciﬁed deﬁnition of other ischemic coronary terms
such as “acute coronary syndrome,” “ischemic coronary
event,” or “unstable angina.” Overall, the entire cohort of
oral DTIs was associated with a signiﬁcantly higher rate of
MI compared with warfarin. MI was reported in 285 of
23,333 subjects treated with oral DTIs versus 133 of 16,024
subjects treated with warfarin, with an OR of 1.35 (95% CI
1.10 to 1.66), p ¼ 0.005 using the ﬁxed-effects model.
There was no signiﬁcant heterogeneity among the studies
(Q¼ 15.3, degree of freedom [DF]¼ 9, I2¼ 41.1% and P¼
0.084 for heterogeneity; Figure 2). Among the 4 trials that
compared dabigatran to warfarin, there were signiﬁcantly
higher rates of MI among those randomized to dabigatran.
Figure 2. Forest plot of risk of MI in trials with oral DTIs compared with warfarin. *Combined dabigatran 150 and 110 mg results from the revised version of
the study.2 EXULT ¼ Exanta Used to Lessen Thrombosis; MH ¼ Mantel-Haenszel method; RE-ALIGN ¼ The Randomized, phase II study to Evaluate the
sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacement; RE-COVER ¼ Dabigatran versus Warfarin in the
Treatment of Acute Venous Thromboembolism; RE-MEDY ¼ Extended Use of Dabigatran Warfarin or Placebo in Venous Thromboembolism; THRIVE ¼
Thrombin Inhibitor in Venous Thromboembolism
Table 1
Characteristics of the included randomized controlled trials of oral direct thrombin inhibitor compared with warfarin
Study Name Population Design Primary End Point Number of
Subjects
Prespeciﬁed
MI Deﬁnition*
Thrombin Inhibitor† Duration
(Mo)
RE-LY2 Atrial ﬁbrillation Noninferiority
open label
Stroke and SE 18,113 Yes Dabigatran 150 and
110 mg BID
24
RE-COVER7 Acute VTE Noninferiority
double blind
VTE or related death 2,539 No Dabigatran 150 mg BID 6
RE-MEDY8 VTE Noninferiority
double blind
VTE or related death 2,866 z Dabigatran 150 mg BID
or placebo
18
RE-ALIGNx Mechanical valves Phase II,
open label
Mortality and morbidity 249k No{ Dabigatran 150, 220, and
300 mg BID
3
SPORTIF III9 Atrial ﬁbrillation Noninferiority
open label
Stroke and SE 3,410 Yes Ximelagatran 36 mg BID 17.4
SPORTIF V10 Atrial ﬁbrillation Noninferiority
double blind
Stroke and SE 3,922 Yes Ximelagatran 36 mg BID 20
THRIVE4 Acute VTE Noninferiority
double blind
Recurrent VTE 2,489 No Ximelagatran 36 mg BID 6
EXULT
A and B11e13
Thromboprophylaxis Superiority
double blind
VTE and all-cause death 3,800 No Ximelagatran 24 and
36 mg BID
1e1.5
Lip et al14 Atrial ﬁbrillation Tolerability and
dose guiding
Bleeding and
adverse events
955 No AZD0837, 150 to 450 mg
QD and 200 mg BID
5
Olsson et al15 Atrial ﬁbrillation Safety and
tolerability
Bleeding and
adverse events
249 No AZD0837, 150 and
300 mg BID
3
BID ¼ twice daily; EXULT ¼ Exanta Used to Lessen Thrombosis; QD ¼ once daily; RE-ALIGN ¼ The Randomized, phase II study to Evaluate the sAfety
and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacement; RE-COVER ¼ Dabigatran versus Warfarin in the Treatment of
Acute Venous Thromboembolism; RE-MEDY ¼ Extended Use of Dabigatran Warfarin or Placebo in Venous Thromboembolism; SE ¼ systemic embolism;
THRIVE ¼ Thrombin Inhibitor in Venous Thromboembolism; VTE ¼ venous thromboembolism.
* The original study publication and additional publications including supplementary appendices and trial design publications were screened for prespeciﬁed
deﬁnition of MI or any related terms as any type of end point or an adverse event after randomization.
† Comparison in this table was against adjusted dose warfarin to an international normalized ratio of 2.0-3.0.
z As per study protocol, all suspected acute coronary syndromes (ACS) were evaluated centrally and blindly by ACS Adjudication Committee. The operating
procedures containing all details regarding ACS will be available as a separate document. This document is currently not available in the public domain.8
x http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm. The study had blinded end point that also included dabigatran plasma drug levels.
k Study was prematurely terminated. The planned study population was 405.
{ An independent adjudication committee was established for the blinded adjudication of MI among other efﬁcacy outcome end points.
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Figure 3. Funnel plot for evaluation of publication bias for comparison
between oral DTIs and warfarin.
Figure 4. Flow diagram of the study selection of primary stroke prevention
atrial ﬁbrillation trials for comparison between warfarin and non-warfarin
anticoagulant.
1976 The American Journal of Cardiology (www.ajconline.org)These included 212 out of 14,954 subjects treated with
dabigatran versus 78 out of 8,803 subjects treated with
warfarin (OR 1.41, 95% CI 1.09 to 1.83, p¼ 0.009, Q¼ 4.5,
DF ¼ 3, I2 ¼ 33.2% and P ¼ 0.21 for heterogeneity).
In the 5 trials comparing ximelagatran versus warfarin,
there was a trend toward increased rates of MI among those
treated with ximelagatran but subgroup meta-analysis
did not reach statistical signiﬁcance. There were 70 out of
7,581 in the ximelagatran group compared with 54 out of
6,821 in the warfarin group (OR 1.23, 95% CI 0.86 to 1.76,
p ¼ 0.25, Q ¼ 10.3, DF ¼ 3, I2 ¼ 70.8% and P ¼ 0.016 for
heterogeneity). Among the trials with ximelagatran, the
meta-analysis by treatment indication revealed more than 3
times increased risk of MI for those treated with ximela-
gatran compared with warfarin in the subgroup of venous
thromboembolism and thromboprophylaxis. There were 20
MIs out of 3,917 subjects treated with ximelagatran versus 4
out of 3,156 subjects treated with warfarin (OR 3.46, 95%
CI 1.25 to 9.57, p¼ 0.017, Q¼ 0.53, DF¼ 1, I2¼ 0.0% and
P ¼ 0.46 for heterogeneity).
Among the trials with AZD0837, there was no signiﬁcant
difference between rates of MI among the groups. Therewere 3 MIs out of 798 subjects treated with AZD0837
versus 1 out of 400 subjects treated with warfarin (OR 1.17,
95% CI 0.17 to 7.94, p ¼ 0.87, Q ¼ 0.036, DF ¼ 1, I2 ¼
0.0% and P ¼ 0.85 for heterogeneity).
Inﬂuence analysis of the entire cohort demonstrated that
none of the individual studies appeared to have signiﬁcant
impacts on the overall combined effect sizes ranging from
1.29 to 1.54 (p value ranging from 0.0 to 0.034) for ﬁxed
effect. There was no evidence of signiﬁcant publication bias
demonstrated by funnel panel and Egger regression test
intercept at 0.90, p ¼ 0.13 (2 tailed) (Figure 3).
The results of the literature search on warfarin versus
comparator anticoagulant are shown in Figure 4. We
identiﬁed 564 published reports and reviewed 18 full-text
manuscripts. Eight randomized controlled trials fulﬁlled
the inclusion criteria and were selected for meta-analysis
with the total number of 69,615 participants. The
comparator in different studies included aspirin with and
without clopidogrel, oral and parenteral factor Xa inhibi-
tors, and oral DTIs. The individual study details are out-
lined in Table 2. There was signiﬁcant heterogeneity
among the studies with Q ¼ 15.9, DF ¼ 7, I2 ¼ 56.1%, P ¼
0.026. Overall, subjects treated with warfarin had similar
rate of MI than those treated with comparator agents. There
were 403 out of 31,867 subjects treated with warfarin
compared with 503 out of 37,748 subjects treated with
comparator agents (OR 1.06, 95% CI 0.85 to 1.34, p ¼
0.59), using random-effects model (Figure 5). Inﬂuence
analysis demonstrated that none of the individual studies
appeared to have signiﬁcant impacts on the overall
combined effect sizes ranging from 1.01 to 1.14 (p value
ranging from 0.31 to 0.92) for random effect. There was no
evidence of signiﬁcant publication bias demonstrated by
funnel panel and Egger regression test, intercept at 1.29,
p ¼ 0.38 (2 tailed) (Figure 6).
Discussion
In the present meta-analysis, we have demonstrated that
oral DTIs as a group were associated with an increased risk
of MI compared with warfarin among 39,357 patients
analyzed. To our knowledge, this is the ﬁrst analysis to
extend the ﬁndings of an increased risk of MI with
dabigatran to other oral thrombin inhibitors. The second
meta-analysis on 69,615 subjects showed no signiﬁcant
difference in the rates of MI among those treated with
warfarin versus those in the combined cohort of aspirin
alone, aspirin plus clopidogrel, factor Xa inhibitors, and oral
DTIs. Hence, the increased risk of MI among patients
treated with oral DTIs versus their counterparts treated with
warfarin is likely due to a class effect of oral DTIs and not
due to protective effect of warfarin.
The present meta-analysis differs from previous reports
evaluating the risk of MI among those treated with dabi-
gatran because we were able to include the results from the
recently published randomized trials on Extended Use of
Dabigatran Warfarin or Placebo in Venous Thromboembo-
lism and The Randomized phase II study to Evaluate the
safety and pharmacokinetics of oral dabigatran etexilate in
patients after heart valve replacement (Table 1). The list of
trials included in the present analysis provides the most
Table 2
Characteristics of the included randomized controlled primary stroke prevention trials of warfarin compared with non-warfarin anticoagulant*
Study Name Design Primary End Point Number of
Participants
Prespeciﬁed
MI Deﬁnition
Comparator Regimen* Duration (Mo)
AMADEUS16 Noninferiority
open label
Stroke and SE 4,576 No Idraparinux 2.5 mg SC once weekly 10.7
ACTIVE W17 Noninferiority
open label
Stroke and SE, MI and
vascular death
6,706 Yes Clopidogrel 75 and aspirin 75e100 mg daily 15.4
BAFTA18 Randomized
open label
Fatal or disabling stroke, SE 937 No Aspirin 75 mg daily 32.4
ROCKET AF19 Noninferiority
double blind
Stroke and SE 14,264 Yes Rivaroxaban 20 mg daily 23.2
ARTISTOTLE20 Noninferiority
double blind
Stroke and SE 18,201 No Apixaban 5 mg twice daily 21.6
ACTIVE ¼ Atrial ﬁbrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events; AMADEUS ¼ Comparison of idraparinux with vitamin K
antagonists for prevention of thromboembolism in patients with atrial ﬁbrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thrombo-
embolic Events in Atrial Fibrillation; BAFTA ¼ Birmingham Atrial Fibrillation Treatment of the Aged Study; ROCKET AF ¼ Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SC ¼ subcutaneously;
SE ¼ systemic embolism.
* Comparison in this table was against adjusted dose warfarin to an international normalized ratio of 2.0-3.0. For characteristics data on RE-LY, SPORTIF III
and V trials, please see Table 1.
Figure 5. Forest plot of risk of MI in primary stroke prevention atrial ﬁbrillation trials for comparison between warfarin and non-warfarin anticoagulant.
*Combined dabigatran 150 and 110 mg results from the revised version of the study.2 ACTIVE ¼ Atrial ﬁbrillation Clopidogrel Trial with Irbesartan for
prevention of Vascular Events; AMADEUS¼ Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial
ﬁbrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; BAFTA ¼ Birmingham Atrial
Fibrillation Treatment of the Aged Study; MH ¼ Mantel-Haenszel method; ROCKET AF ¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.
Review/Risk of MI from DTIs: A Meta-Analysis 1977updated collection of trials with dabigatran against warfarin
for any indication and allows a reliable exclusive meta-
analysis of dabigatran versus warfarin not previously dis-
played. The relative risk of MI for a patient treated with
dabigatran for any indication compared with warfarin is
41%, and the absolute risk difference remains small at
0.53%. The number needed to treat to cause 1 MI compared
with warfarin is 188.
The open-labeled Stroke Prevention trial using an Oral
Thrombin Inhibitor Ximelagatran in Atrial Fibrillation
(SPORTIF) III and double-blinded SPORTIF V trial
demonstrated divergent MI outcomes.9,10 Hylek et al21
have argued that the disparate results in the two SPORTIFtrials may have been due to much tighter control of the
cardiovascular risk factors in the SPORTIF V trial, which
is the only outlier in both the ximelagatran subgroup and
the entire group of thrombin inhibitors (Figure 3).
In the phase II trial with AZD0837 by Olsson et al, the
overall cardiac-related events including angina, MI, atrial
or ventricular arrhythmias, and cardiac arrest occurred in 7
subjects treated with AZD0837 compared with 0 cardiac
events in subjects treated with warfarin. It is unclear based
on the data publicly available whether these events were
primarily caused by ischemia alone or separate possible
arrhythmogenic properties of AZD0837, but the signal
with increased coronary events seems to be present with
Figure 6. Funnel plot for evaluation of publication bias for comparison
between warfarin and non-warfarin anticoagulants in primary stroke
prevention atrial ﬁbrillation trials.
1978 The American Journal of Cardiology (www.ajconline.org)this agent as well. To our knowledge, there are no further
ongoing phase II or III trials with AZD0837.22
In a meta-analysis on contemporary atrial ﬁbrillation
stroke prevention trials by Lip et al5 from 2010, the
investigators hypothesized that warfarin might have
a protective effect against MI compared with non-warfarin
anticoagulants. The limitation of the latter study was that
the results of Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARIS-
TOTLE) and Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibril-
lation (ROCKET-AF) trials were not included since the
data were not yet available in 2010. The conclusion by Lip
et al was therefore likely to be driven by the oral DTI effect
from the RE-LY and SPORTIF trials.
The question is could this observation be due to
a certain mechanism/s related to the direct thrombin inhi-
bition23? Evidently, there are 2 different classes of the
DTIs: the bivalent including hirudin and bivalirudin and
univalent including argatroban, ximelagatran, and dabiga-
tran.24 It has been proposed that melagatran may dissociate
from thrombin, leaving some amount of free enzymatically
active thrombin available for hemostatic interactions.25
Furugohri et al26 demonstrated that at certain lower con-
centrations melagatran enhanced thrombin generation in
human plasma, but at higher concentrations, melagatran
inhibited the thrombin generation as expected. This
enhancement of thrombin generation was dependent on
thrombomodulin and activated protein C concentrations.
The investigators hypothesized the enhancement of
thrombin generation being due to the suppression of the
thrombin-thrombomodulin-induced negative feedback
system by inhibiting protein C activation. In contrast, the
factor Xa inhibitors fondaparinux and edoxaban demon-
strated consistently increasing inhibition of thrombin
generation in a nonlinear dose-dependent fashion. Dale
et al27 demonstrated a greater reduction in peak thrombin
generation and endogenous thrombin potential at different
in vitro concentrations of tissue factor in plasma from 18
warfarin-treated patients compared with 36 dabigatran-
treated patients who entered the RE-LY trial. The differ-
ence in relative inhibition between warfarin and dabigatranwas greatest at higher tissue factor concentrations favoring
warfarin. What continues to be unknown is the degree of
the platelet activation by any measure among the patients
who did have MI while treated with dabigatran, and
whether addition of aspirin would alleviate the small risk
of MI for subjects treated with dabigatran.
A hypothesis unifying these latest observations could be
proposed indicating that at trough levels of univalent DTIs,
the remaining enzymatically active thrombin dissociated from
DTI molecules when exposed to tissue factor at the site of the
ruptured plaque, or a mechanical valve may generate more
thrombin formation and may potentially contribute to platelet
activation while thrombin-induced negative feedback system
through the inhibition of protein C activation may still be
inhibited by the oral DTI with insufﬁcient amount of circu-
lating DTI molecules to counter the thrombin generation.
Further studies are required to verify such hypothesis.
This study has certain limitations. This was primarily
a meta-analysis for the purpose of hypothesis generation on
trials in which MI was not an a priori end point. The study
was limited by the number of studies included. On the
comparison between thrombin inhibitors and warfarin,
there were only 11 studies analyzed. Although the RE-LY
trial had a relative weight of 62%, the inﬂuence analysis
revealed that the result of the meta-analysis was consistent
even without the RE-LY data. The study was further
limited by limited information provided about MI events in
individual trials that were screened including time to event.
In the Exanta Used to Lessen Thrombosis (EXULT) trials,
the MI data were not disclosed in the original publications
and were extracted from a later published Food and Drug
Administration report.13 The Dabigatran With or Without
Concomitant Aspirin compared with Warfarin alone in
patients with nonvalvular Atrial Fibrillation (PETRO) trial,
not included in this analysis, reported 7 cases of angina; of
which, 2 were classiﬁed as acute coronary syndrome in the
arms with various doses of dabigatran compared with no
ischemic events in the warfarin arm. Yet, the deﬁnition of
MI, angina, or acute coronary syndrome was not pre-
speciﬁed in the trial design.28 It is imperative for the future
studies on any class of antithrombotics to speciﬁcally
disclose clear, unequivocal, and unbundled data on all
types of thromboembolic adverse events including MI at
all phases of development.Acknowledgment: We would like to thank Ms. Donna
Philips for her assistance in proofreading the manuscript.Disclosures
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